1. Neurologic toxicity associated with high dose metronidazole therapy;Frytak, S.; Moertel, C.G.; Childs, D.S.; Albers, J.W.;Ann Intern Med,1978
2. Central nervous system toxicity associated with metronidazole therapy;Kusumi, R.K.; Plouffe, J.F.; Wyatt, R.H.; Fass, R.J.;Ann Intern Med,1980
3. Convulsions associated with high cumulative doses of metronidazole;Halloran, T.J.;Drug Intell Clin Pharm,1982
4. Selective injury to Purkinje cells in the dog after oral administration of highdose metronidazole derivative;Scharer, K.;(Original in German.) Verh Dtsch Ges Pathol,1972
5. Enzyme markers in acute non-lymphoid leukaemia We read with interest the recent review in the journal by Dr Drexler et al.' It is stated that "the main group AML did not show one distinct enzyme marker phenotype". While this may be true for the purine salvage enzymes, we would like to draw attention to the use of certain lysosomal enzymes in the diagnosis and classification of acute myeloid leukaemias in both adults2 and children.3 We have now studied 57 patients with acute non-lymphoid leukaemia and have measured the activities and isoenzyme profiles for the enzymes f3 hexosaminidase and a mannosidase. A summary of our results is shown in the table. Patients with AML, AMMOL, and AMOL showed significant increases in these enzyme activities when compared with peripheral blood granulocytes or leukaemic cells of lymphoid origin. Moreover, in patients with AML in particular there was a reduction in f hexosaminidase B isoenzyme peak when compared with the A component